FDA com­mis­sion­er says drug prices are too high, calls for bet­ter ev­i­dence gen­er­a­tion

FDA Com­mis­sion­er Rob Califf told BIO CEO Rachel King on Wednes­day that it’s “im­pos­si­ble to ar­gue that the US is do­ing well in health,” high­light­ing high drug prices and mis­in­for­ma­tion as two key chal­lenges.

The com­mis­sion­er al­so took the op­por­tu­ni­ty to dis­cuss ac­cel­er­at­ed ap­proval re­forms, at­tri­tion at the agency and the In­fla­tion Re­duc­tion Act, which came in­to fo­cus ear­li­er this week when Mer­ck filed a law­suit call­ing parts of the drug pric­ing law a sham. In­dus­try crit­ics have ar­gued that the leg­is­la­tion will have a chill­ing ef­fect on in­no­va­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER